The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNorth Atl.smlr Regulatory News (NAS)

Share Price Information for North Atl.smlr (NAS)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3,820.00
Bid: 3,730.00
Ask: 3,790.00
Change: 40.00 (1.06%)
Spread: 60.00 (1.609%)
Open: 3,720.00
High: 3,820.00
Low: 3,710.00
Prev. Close: 3,780.00
NAS Live PriceLast checked at -
North Atlantic Smaller Companies is an Investment Trust

To provide capital appreciation through investment in a portfolio of smaller companies principally based in countries bordering the North Atlantic Ocean.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-year Report

15 Sep 2023 07:00

RNS Number : 5097M
North Atlantic Smlr Co Inv Tst PLC
15 September 2023
 

North Atlantic Smaller Companies Investment Trust plc

Half-Yearly Report for the six months ended 31 July 2023

Registered in England and Wales number 1091347

 

objective of the company and financial highlights

North Atlantic Smaller Companies Investment Trust plc is a company incorporated and registered in England and Wales.

The objective of the Company is to provide capital appreciation through investment in a portfolio of smaller companies principally based in countries bordering the North Atlantic Ocean.

31 July

2023

(unaudited)

31 January

2023

(audited)

%

Change

Net asset value ("NAV") per 5p Ordinary Share*:

 

Basic and diluted

4,929p

5,097p

(3.3)

Basic and diluted adjusted#

5,174p

5,236p

(1.2)

Mid-market price of the 5p Ordinary Shares

3,900p

3,900p

-

Discount to net asset value

20.9%

23.5%

Discount to adjusted net asset value

24.6%

25.5%

Standard & Poor's 500 Composite Index†

3,569.00

3,307.30

7.9

Russell 2000 Index†

1,557.90

1,567.40

(0.6)

Ongoing charges (annualised)

1.2%

1.4%

 

* Includes current period.

# Adjusted to reflect Oryx International Growth Fund plc ("Oryx") under the equity method of accounting, which is how the Company previously accounted for its share of Oryx, prior to the adoption of IFRS 10. This is useful to the shareholder as it shows the NAV based on valuing Oryx at NAV. See note 6.

† Sterling adjusted.

 

 

chief executive's review

During the six months under review the net asset value fell by 1.2% due entirely to the fall in the dollar relative to sterling of 4.4%. The Standard & Poors Dollar Adjusted Index rose almost entirely due to seven large megacaps to which the portfolio had no exposure.

Performance compared against appropriate UK indices where the majority of the portfolio is invested remains favourable.

The Trust reported net income for the period of £4,615,000 (2022 £462,000 loss). Consistent with prior years, no dividend is being declared at this stage although the Board intends to declare an interim dividend in February when the results for the year become clearer. Based on current expectations, it is anticipated that dividends in respect of the financial year ending January 2024 will comfortably exceed that paid in respect of fiscal 2023.

During the six month period the Trust purchased approximately 95,000 shares for cancellation at a discount to NAV of approximately 25%. This policy which is ongoing increased the net asset value for all long term shareholders and helped to modestly reduce the discount compared to the end January 2023 net asset value at a time when many other trusts, particularly those with unquoted holdings, have seen a significant widening.

quoted portfolio

The market for quoted investments has been particularly tough over the past six months as evidenced by the weakness in the various small cap indices. The reasons for this are numerous but can be summed up as follows: weak economic growth, rising interest rates and very significant redemptions in small cap funds with negligible retail demand. It is therefore pleasing to note that the quoted portfolio significantly outperformed falling by about 3%.

Oryx and Odyssean taken together rose modestly, helped in particular by encouraging performance in Oryx. The Trust's stand out success stories were NIOX which rose by 75% following multiple earnings upgrades and Sureserve rising over 40% following a successful takeover.

The principal disappointment was EKF which fell 30% as the business repositions itself post COVID. Fund management stocks were also disappointing with Assetco in particular notably weak. In the United States Mountain Commerce fell 35% following turmoil in the banking industry. Despite the fall the bank continues to perform well with negligible bad debt.

unquoted portfolio

Despite industry wide concerns relating to unquoted investments, the portfolio continued to perform well during the period mainly due to our zero exposure to technology stocks. Taken as a whole, the unquoted portfolio added approximately £7m to the value of the Fund with the standout performance coming from Spring (following outstandingly good results) +80% and Harwood Private Equity V +8%.

Taken as a whole, the private equity funds continue to perform well and should create further uplifts combined with significant cash inflow into the Trust during the balance of the year.

conclusion

At the end of June 2023 the Trust had approximately £107m in cash broadly in line with the January 2023 position despite the weakness in the dollar. We continue to believe that there is significant value in our portfolio which should be well placed to weather the very difficult economic environment facing the UK.

A number of our unquoteds are in a sale process which should support increases in both net asset value per share and liquidity as the year progresses.

Finally, the Trust's substantial cash reserves will enable it to benefit from a more benign investing environment in the future.

C H B Mills

Chief Executive

14 September 2023

top ten investments as at 31 July 2023

Fair

value

£'000

% of

net assets

Oryx International Growth Fund Limited*

UK Listed

81,494

12.2

US Treasury Bills

US Treasury Stock

80,612

12.1

Harwood Private Equity Fund V LP

UK Unquoted

49,015

7.4

Polar Capital Holdings plc

UK Quoted on AIM

33,950

5.1

Hargreaves Services Plc

UK Quoted on AIM

29,903

4.5

Ten Entertainment Group plc

UK Listed

29,500

4.4

EKF Diagnostics Holdings plc

UK Quoted on AIM

25,680

3.9

Odyssean Investment Trust Plc

UK Listed

25,440

3.8

Niox Group

UK Listed

25,350

3.8

MJ Gleeson Group plc

UK Listed

23,045

3.5

403,989

60.7

 

* Traded price under IFRS 10, incorporated in Guernsey.

All investments are valued at fair value.

 

interim management report

investment objective

The objective of North Atlantic Smaller Companies Investment Trust PLC is to provide capital appreciation to its shareholders through investing in a portfolio of smaller companies which are principally based in countries bordering the North Atlantic Ocean.

material events

The decline in COVID testing has had a material impact on some of the Company's investments, and the war in Russia has created inflation which has impacted markets in the UK and elsewhere.

material transactions

There were no material transactions during the period.

risk profile

The principal risks and uncertainties for the remaining six months of the year continue to be as described in the Annual Report for the year ended 31 January 2022. The principal risks arising from the Company's financial instruments are market price risk, including currency risk, interest rate risk and other price risk, liquidity risk and credit risk. The Directors review and agree policies with the Manager, Harwood Capital LLP, for managing these risks. The policies have remained substantially unchanged in the six months since the year end.

The Company does not have any significant exposure to credit risk arising from any one individual party. Credit risk is spread across a number of counterparties, each having an immaterial effect on the Company's cash flows, should a default happen. The Company assesses the credit worthiness of its debtors from time to time to ensure that they are neither past due or impaired.

To support its investment in unquoted companies, the Company may periodically agree to guarantee all or part of the borrowings of investee companies. Provision is made for any costs that may be incurred when the Directors consider it likely that the guarantee will crystallise.

The Company's exposure to market price risk comprises mainly movements in the value of the Company's investments. It should be noted that the prices of options tend to be more volatile than the prices of the underlying securities. The Manager assesses the exposure to market risk when making each investment decision and monitors the overall level of market risk on the whole of the investment portfolio on an ongoing basis.

The functional and presentational currency of the Company is Sterling, and therefore, the Company's principal exposure to foreign currency risk comprises investments priced in other currencies, principally US Dollars.

The Company invests in equities and other investments that are realisable.

related party transactions

These are listed in note 9 to the half yearly condensed financial statements on page •.

By Order of the Board

Sir Charles Wake Chairman

14 September 2023

 

responsibility statement

The Directors confirm to the best of their knowledge that:

· The condensed set of financial statements contained within this half yearly financial report have been prepared in accordance with International Accounting Standard ("IAS") 34 'Interim Financial Reporting' in conformity with the requirement of the Companies Act 2006 and gives a true and fair view of the assets, liabilities, financial position and profit of the Company; and

· The half yearly financial report includes a fair review of the information required by the FCA's Dis-closure and Transparency Rule 4.2.7R being disclosure of important events that have occurred during the first six months of the financial year, their impact on the condensed set of financial statements and a description of the principal risks and uncertainties for the remaining six months of the year; and

· The half yearly financial report includes a fair review of the information required by the Disclosure and Transparency Rule 4.2.8R being disclosure of related party transactions during the first six months of the financial year, how they have materially affected the financial position of the Company during the period and any changes therein.

The half yearly financial report was approved by the Board on 14 September 2023 and the above responsibility statement was signed on its behalf by:

Sir Charles Wake

Chairman

14 September 2023

 

condensed statement of comprehensive income (unaudited)

Six months ended31 July2023

Six months ended31 July2022

Year ended31 January2023

Revenue£'000

Capital£'000

Total£'000

Revenue£'000

Capital£'000

Total£'000

Revenue£'000

Capital£'000

Total£'000

Income

8,922

-

8,922

4,311

-

4,311

14,068

-

14,068

Net losses on investments at fair value

-

(27,643)

(27,643)

-

(112,555)

(112,555)

-

(99,450)

(99,450)

Currency exchange (losses)/gains

-

(669)

(669)

-

3,805

3,805

-

3,954

3,954

 

 

 

total income

8,922

(28,312)

(19,390)

4,311

(108,750)

(104,439)

14,068

(95,496)

(81,428)

 

 

 

Expenses

 

 

 

Investment management fee (note 9)

(3,561)

-

(3,561)

(3,976)

-

(3,976)

(8,000)

-

(8,000)

Other expenses

(731)

-

(731)

(780)

-

(780)

(1,560)

-

(1,560)

 

 

 

return before taxation

4,630

(28,312)

(23,682)

(445)

(108,750)

(109,195)

4,508

(95,496)

(90,988)

 

 

 

Taxation

(15)

-

(15)

(17)

-

(17)

(50)

-

(50)

 

 

 

return for the period

4,615

(28,312)

(23,697)

(462)

(108,750)

(109,212)

4,458

(95,496)

(91,038)

 

 

 

 

earnings per ordinary share (note 5)

 

 

 

Basic and diluted

 

(174.9p)

(799.4p)

(666.8p)

 

The total column of the statement is the Statement of Comprehensive Income of the Company prepared in accordance with International Financial Reporting Standards ("IFRS") in conformity with the requirement of the Companies Act 2006.

The supplementary revenue and capital columns are presented for information purposes as recommended by the Statement of Recommended Practice ("SORP") issued by the Association of Investment Companies ("AIC").

All items in the above Statement derive from continuing operations. No operations were acquired or discontinued in the period.

The accompanying notes are an integral part of these financial statements.

 

condensed statement of changes in equity (unaudited)

 

Sharecapital£'000

Capital

redemption

reserve£'000

Share

premium£'000

Capital

reserve£'000

Revenuereserve£'000

Total£'000

six months ended 31 July 2023

 

 

 

 

 

 

31 January 2023

680

190

1,301

685,504

5,681

693,356

Total comprehensive income for the period

-

-

-

(28,312)

4,615

(23,697)

Shares purchased for cancellation

(4)

4

-

(2,828)

-

(2,828)

 

 

 

 

 

 

31 July 2023

676

194

1,301

654,364

10,296

666,831

six months ended 31 July 2022

31 January 2022

683

187

1,301

783,080

4,215

789,466

Total comprehensive income for the period

-

-

-

(108,750)

(462)

(109,212)

Shares purchased for cancellation

-

-

-

-

-

-

31 July 2022

683

187

1,301

674,330

3,753

680,254

year ended 31 January 2023

31 January 2022

683

187

1,301

783,080

4,215

789,466

Total comprehensive income for the year

-

-

-

(95,496)

4,458

(91,038)

Shares purchased for cancellation

(3)

3

-

(2,080)

-

(2,080)

Dividend

-

-

-

-

(2,992)

(2,992)

31 January 2023

680

190

1,301

685,504

5,681

693,356

 

The accompanying notes are an integral part of these financial statements.

 

condensed balance sheet (unaudited)

As at31 July2023£'000

As at31 July2022£'000

As at31 January2023£'000

non current assets

 

Investments at fair value through profit or loss

635,150

647,425

685,491

 

635,150

647,425

685,491

current assets

 

Trade and other receivables

6,329

2,927

2,553

Cash and cash equivalents

27,699

34,723

9,010

 

34,028

37,650

11,563

 

total assets

669,178

685,075

697,054

 

current liabilities

 

Trade and other payables

(2,347)

(4,821)

(3,698)

 

total liabilities

(2,347)

(4,821)

(3,698)

 

total assets less current liabilities

666,831

680,254

693,356

 

net assets

666,831

680,254

693,356

 

represented by:

 

Share capital

676

683

680

Capital redemption reserve

194

187

190

Share premium account

1,301

1,301

1,301

Capital reserve

654,364

674,330

685,504

Revenue reserve

10,296

3,753

5,681

 

total equity attributable to equity holders of the company

666,831

680,254

693,356

net asset value per ordinary share (note 6):

 

Basic and diluted

4,929p

4,980p

5,097p

 

The accompanying notes are an integral part of these financial statements.

condensed cash flow statement (unaudited)

Six months ended31 July2023£'000

Six months ended31 July2022£'000

Year ended31 January2023£'000

cash flows from operating activities

 

Investment income received

6,752

2,961

12,903

Deposit interest received

96

16

152

Investment Manager's fees and performance fees paid

(3,517)

(4,025)

(8,025)

Other cash payments

(876)

(600)

(1,356)

 

cash received/(expended) from operations (note 7)

2,455

(1,648)

3,674

Taxation paid

(15)

(17)

(50)

 

net cash inflow/(outflow) from

 

operating activities

2,440

(1,665)

3,624

 

cash flows from investing activities

 

Purchases of investments

(204,318)

(230,835)

(592,922)

Sales of investments

227,331

186,930

520,245

 

net cash inflow/(outflow) from investing activities

23,013

(43,905)

(72,677)

 

cash flows from financing activities

 

Dividend paid

(2,992)

-

-

Repurchase of Ordinary Shares for cancellation

(2,828)

-

(2,080)

 

net cash outflow from financing activities

(5,820)

-

(2,080)

 

 

increase/(decrease) in cash and cash equivalents for the period

19,633

(45,570)

(71,133)

cash and cash equivalents at the start of the period

9,010

76,029

76,029

Revaluation of foreign currency balances

(944)

4,264

4,114

 

cash and cash equivalents at the end of the period

27,699

34,723

9,010

 

 

 

The accompanying notes are an integral part of these financial statements.

 

notes to the financial statements (unaudited)

1. a) basis of accounting

North Atlantic Smaller Companies Investment Trust plc is a company incorporated and registered in England and Wales. The principal activity of the Company is that of an investment trust company within the meaning of Sections 1158/1159 of the Corporation Tax Act 2010.

The condensed financial statements of the Company have been prepared in accordance with International Accounting Standard ("IAS") 34 - "Interim Financial Reporting" in conformity with the requirement of the Companies Act 2006. The accounting policies and methods of computation followed in these half-yearly condensed financial statements are consistent with the most recent annual financial statements for the year ended 31 January 2023 included in the Annual Report.

The financial statements have also been prepared in accordance with the AIC SORP for the financial statements of investment trust companies and venture capital trusts, except to any extent where it is not consistent with the requirements of IFRS.

The financial information contained in this Half-Yearly Report does not constitute statutory accounts as defined in the Companies Act 2006. The financial information for the periods ended 31 July 2023 and 31 July 2022 have not been audited or reviewed by the Company's Auditor. The figure and financial information for the year ended 31 January 2023 are an extract from the latest published audited financial statements, which have been filed with the Registrar of Companies. The report of the Auditor on those financial statements was unqualified and did not contain a statement under either Section 498(2) or 498(3) of the Companies Act 2006.

b) functional currency

The functional currency of the Company is Pounds Sterling because this is the primary economic currency in which the Company operates. The financial statements are presented in Pounds Sterling rounded to the nearest thousand, except where otherwise indicated.

c) significant accounting policies

The accounting policies applied are consistent with those of the Annual Financial Report for the year ended 31 January 2023. Since the year end no new standards have been adopted.

d) accounting developments

In the current period, the Company has applied a number of amendments to IFRS, issued by the IASB mandatorily effective for an accounting period that begins on or after 1 January 2023. These include annual improvements to IFRS, changes in standards, legislative and regulatory amendments, changes in disclosure and presentation requirements. The adoption of these has not had any material impact on these condensed financial statements.

e) segmental reporting

The Directors are of the opinion that the Company is engaged in a single segment of business, being investment business. The Company invests in smaller companies principally based in countries bordering the North Atlantic Ocean.

f) going concern

The financial statements have been prepared on a going concern basis and on the basis that approval as an investment trust company will continue to be met. The Directors have made an assessment of the Company's ability to continue as a going concern and are satisfied that the Company has the resources to continue in business for the foreseeable future, being a period of 12 months from the date when these financial statements were approved. The longer-term economic effects of the pandemic are very difficult to predict but in considering preparing the accounts on a going concern basis the Directors noted the Company holds a portfolio of liquid investments whose value is a multiple of liabilities. The Directors are of the view that the Company can meet its obligations as and when they fall due. The cash and US treasury bills available enables the Company to meet any funding requirements and finance future additional investments. The Company is a closed-end fund, where assets are not required to be liquidated to meet day-to-day redemptions.

2. investment management and performance fees

A Performance Fee is only payable if the investment portfolio, including Oryx at the adjusted price, outperforms the Sterling adjusted Standard & Poor's 500 Composite Index at the end of each financial year and is limited to a maximum payment of 0.5% of Shareholders' Funds, and is allocated 100% to capital.

An amount would be included in these financial statements for the Performance Fee that could be payable based on investment performance to 31 July 2023. At that date, no Performance Fee, inclusive of VAT, has been accrued for in the accounts (31 July 2022: £nil; 31 January 2023: £nil).

Further details of fees paid to the investment manager can be found in Note 9, Related Party transactions.

3. taxation

The Company has an effective tax rate of 0%. The estimated effective tax rate is 0% as investment gains are exempt from tax owing to the Company's status as an Investment Trust and there is expected to be an excess of management expenses over taxable income and thus there is no charge for corporation tax.

During the half year to 31 July 2023, the Company recognised a total charge of £15,000 (half year to 31 July 2022: £17,000, year ended 31 January 2023: £50,000), representing irrecoverable withholding tax paid on overseas investment income.

4. dividends

For the year ended 31 January 2023, the Board declared an interim dividend of 22p per Ordinary share (31 January 2022: nil) which was paid on 24 February 2023. For the year end 31 January 2023, no final dividend was proposed (31 January 2022; nil).

 

5. earnings per ordinary share

 

Revenue

Capital

Total

Netreturn£'000

OrdinaryShares

PerSharepence

Netreturn£'000

OrdinaryShares

PerSharepence

Netreturn£'000

OrdinaryShares

PerSharepence

six months ended 31 July 2023

 

Basic and diluted return per Share

4,615

13,546,346

34.1

(28,312)

13,546,346

(209.6)

(23,697)

13,546,346

(174.9)

 

sixmonths ended 31 July 2022

Basic and diluted return per Share

(462)

13,661,000

(3.4)

(108,750)

13,661,000

(796.0)

(109,212)

13,661,000

(799.4)

year ended 31 January 2023

 

Basic and diluted return per Share

4,458

13,653,763

32.6

(95,496)

13,653,763

(699.4)

(91,038)

13,653,763

(666.8)

 

Basic return per Ordinary Share has been calculated using the weighted average number of Ordinary Shares in issue during the period.

6. net asset value per ordinary share

The basic net asset value per Ordinary Share is based on net assets of £666,831,000 (31 July 2022: £680,254,000; 31 January 2023: £693,356,000) and on 13,527,634 Ordinary Shares (31 July 2022: 13,661,000; 31 January 2023: 13,602,068) being the number of Ordinary Shares in issue at the period end.

During the period to 31 July 2023, there were 74,434 shares bought back for cancellation at a cost, including stamp duty of £2,828,000 (31 July 2022: no shares bought back for cancellation; 31 January 2023: 58,932 shares at a cost, including stamp duty of £2,080,000).

adjustment for Oryx

The Company has also reported an adjusted net asset value per share using equity accounting, in accordance with its previous method of valuing its investment in Oryx. The Company has chosen to report this net asset value per share to show the difference derived if equity accounting were to be used. Equity accounting permits the use of net asset value pricing for listed assets which in the case of Oryx is higher than its fair value.

 

The values of Oryx, as at each period end, are as follows:

31 July 2023 £'000

31 July 2022 £'000

31 January 2023 £'000

Oryx at Fair value (traded price)

81,494

89,207

91,819

Oryx value using Equity Accounting

114,534

107,270

110,625

Increase in net assets using Equity Accounting

33,040

18,063

18,806

 

31 July 2023

31 July 2022

31 January 2023

Net asset value per Share

 

- Basic and diluted

4,929p

4,980p

5,097p

 

Net asset value per Share adjusted

 

- Basic and diluted

5,174p

5,112p

5,236p

 

7. reconciliation of total return before taxation to cash expended from operations

Six months

ended

31 July 2023

£'000

Six months

ended

31 July 2022

£'000

Year ended

31 January 2023

£'000

Total return before taxation

(23,682)

(109,195)

(90,988)

Losses on investments

28,312

108,750

95,496

Increase in debtors and accrued income

(2,074)

(1,379)

(1,005)

(Decrease)/increase in creditors and accruals

(101)

176

171

 

Cash expended from operations

2,455

(1,648)

3,674

 

8. investments

financial assets at fair value through profit or loss

This requires the Company to classify fair value measurements using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy consists of the following three levels:

· Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

· Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices).

· Level 3 - Inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The level in the fair value hierarchy within which the fair value measurement is categorised in its entirety is determined on the basis of the lowest level input that is significant to the fair value measurement in its entirety.

For this purpose, the significance of an input is assessed against the fair value measurement in its entirety. If a fair value measurement uses observable inputs that require significant adjustment based on unobservable inputs, that measurement is a Level 3 measurement. Assessing the significance of a particular input to the fair value measurement in its entirety requires judgement, considering factors specific to the asset or liability.

The determination of what constitutes 'observable' requires significant judgement by the Company. The Company considers observable data from investments actively traded in organised financial markets; fair value is generally determined by reference to Stock Exchange quoted market bid prices at the close of business on the Balance Sheet date, without adjustment for transaction costs necessary to realise the asset.

The table below sets out fair value measurements as at the period end, by the level in the fair value hierarchy into which the fair value measurement is categorised.

six months ended 31 July 2023

Total£'000

Level 1£'000

Level 2£'000

Level 3£'000

Equity investments at fair value

524,318

412,203

-

112,115

Fixed interest investments at fair value

110,832

80,612

-

30,220

Total

635,150

492,815

-

142,335

six months ended 31 July 2022

Total£'000

Level 1£'000

Level 2£'000

Level 3£'000

Equity investments at fair value 

526,771

449,256

-

77,515

Fixed interest investments at fair value

120,654

102,358

-

18,296

Total

647,425

551,614

-

95,811

year ended 31 January 2023

Total£'000

Level 1£'000

Level 2£'000

Level 3£'000

Equity investments at fair value

553,609

450,094

-

103,515

Fixed interest investments at fair value

131,882

100,413

-

31,469

Total

685,491

550,507

-

134,984

reconciliation of level 3 movement - financial assets at 31 July 2023

Total£'000

Equity investments£'000

Fixed interest investments£'000

Opening fair value at 31 January 2023

134,984

103,515

31,469

Purchases

3,083

2,882

201

Sales

(43)

(43)

-

Total gains included in gains on investments in the statement of comprehensive income:

 

- on assets sold

(442)

(290)

(152)

- on assets held at the end of the period

4,753

6,051

(1,298)

Closing fair value

142,335

112,115

30,220

unquoted at directors' estimate of fair value

Unquoted investments are valued in accordance with the International Private Equity and Venture Capital Valuation ("IPEV") Guidelines. Their valuation incorporates all factors that market participants would consider in setting a price. The primary valuation techniques employed to value the unquoted investments are earnings multiples, recent transactions and the net asset basis. Valuations in local currency are translated into Sterling at the exchange rate ruling on the Balance Sheet date.

Included within the Statement of Comprehensive Income as at 31 July 2023, is a gain of £5,018,000 relative to the movement in the fair value of the unquoted investments valued using IPEV valuation techniques.

the valuation techniques applied are based on the following assumptions:

Unquoted investments are usually valued by reference to the valuation multiples of similar listed companies or from transactions of similar businesses. Where appropriate discounts are then applied to those comparable multiples to reflect differences in size and liquidity. These enterprise values are then adjusted for net debt to arrive at an equity valuation. Where companies are in compliance with the loan note terms these loans are generally held at par plus accrued interest (where applicable) unless the enterprise value suggests that the debt cannot be recovered.

9. related party transactions

There have been no changes to the related party arrangements or transactions as reported in the Statutory Annual Financial Report for the year ended 31 January 2023.

The Administrator, Harwood Capital LLP, is regarded as a related party of the Company. The amounts incurred by Harwood Capital LLP and Growth Financial Services Limited in respect of investment management for the period are as follows:

Six months ended

31 July 2023

£'000

Six months ended

31 July 2022

£'000

Year ended

31 January 2023

£'000

Fees due to Harwood Capital LLP

2,137

2,376

4,800

Fees due to GFS

1,424

1,600

3,200

Performance fee

-

-

-

Irrecoverable VAT thereon

-

-

-

Irrecoverable VAT thereon - PYA

-

-

-

3,561

3,976

8,000

 

At 31 July 2023, £356,000 was payable to Harwood Capital in respect of outstanding management fees (31 July 2022: £376,000, 31 January 2023: £400,000). At 31 July 2023, there was no fee payable to GFS in respect of outstanding performance fees (31 July 2022: £nil, 31 January 2023: £nil) net of VAT.

Fees paid to Directors, for the six months ended 31 July 2023 amounted to £97,000 (six months ended 31 July 2022: £79,000; year ended 31 January 2023: £170,000).

At 31 July 2023, £18,000 was payable to Directors in respect of outstanding fees (31 July 2022: £13,000, 31 January 2023 £16,000).

 

shareholder information

financial calendar

Announcement of results and annual report

May

Annual General Meeting

June

Half Yearly figures announced

September

Half Yearly Report posted

September

share price

The Company's mid-market share price is quoted daily in the Financial Times appearing under "Investment Companies".

It also appears on:

SEAQ Ordinary Shares: NASTrustnet: www.trustnet.com

net asset value

The latest net asset value of the Company can be found on the Company's website: www.nascit.co.uk

share dealing

Investors wishing to purchase more Ordinary Shares or dispose of all or part of their holding may do so through a stockbroker. Many banks also offer this service.

The Company's registrars are Link Group. In the event of any queries regarding your holding of shares, please contact the registrars on: 0871 664 0300, or by email on enquiries@linkgroup.co.uk

Changes of name or address must be notified to the registrars in writing at:

Link Group

10th Floor

Central Square

29 Wellington Street

Leeds LS1 4DL

Directors

Sir Charles Wake (Chairman)

Christopher Mills (Chief Executive)

Lord Howard of Rising

G Walter Loewenbaum

Peregrine Moncreiffe

Administrator

Harwood Capital LLP

(Authorised and regulated by the Financial Conduct Authority)

6 Stratton Street

Mayfair

London W1J 8LD

Telephone: 020 7640 3200

Financial Adviser and Stockbroker

Winterflood Investment Trusts

The Atrium Building

Cannon Bridge

25 Dowgate Hill

London EC4R 2GA

 

Registered Office

6 Stratton Street

Mayfair

London W1J 8LD

Telephone: 020 7640 3200

Registrars

Link Group

10th Floor

Central Square

29 Wellington Street

Leeds LS1 4DL

Auditors

RSM UK Audit LLP

25 Farringdon Street

London EC4A 4AB

Company Secretary

SGH Company Secretaries Limited

60 Gracechurch Street

London EC3V 0HR

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR EZLFFXKLEBBB
Date   Source Headline
17th Apr 202410:52 amRNSNet Asset Value(s)
12th Apr 20243:48 pmRNSHolding(s) in Company
8th Apr 20249:42 amRNSTransaction in Own Shares
2nd Apr 20247:00 amRNSTransaction in Own Shares
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 202412:45 pmRNSTransaction in Own Shares - Replacement
21st Mar 20247:00 amRNSTransaction in Own Shares
20th Mar 20243:55 pmRNSNet Asset Value(s)
15th Mar 202410:01 amRNSHolding(s) in Company
27th Feb 20247:00 amRNSDirector/PDMR Shareholding
19th Feb 202411:07 amRNSTransaction in Own Shares
19th Feb 20247:00 amRNSDividend Declaration
15th Feb 20247:00 amRNSNet Asset Value(s)
8th Feb 20247:00 amRNSTransaction in Own Shares
5th Feb 20249:14 amRNSNew Investment: Crest Foods
5th Feb 20247:00 amRNSTransaction in Own Shares
31st Jan 20247:00 amRNSDirector/PDMR Shareholding
17th Jan 20243:32 pmRNSNet Asset Value(s)
27th Dec 20237:00 amRNSDirector Declaration
19th Dec 20237:00 amRNSNet Asset Value(s)
6th Dec 20237:41 amRNSInvestment Update: Ten Entertainment Group Plc
16th Nov 202312:44 pmRNSNet Asset Value(s)
30th Oct 20232:30 pmRNSTransaction in Own Shares
23rd Oct 20232:10 pmRNSTransaction in Own Shares
16th Oct 202312:19 pmRNSNet Asset Value(s)
12th Oct 20238:43 amRNSReplacement: Private Equity Investment Disposal
12th Oct 20237:00 amRNSPrivate Equity investment disposal
9th Oct 20233:02 pmRNSTransaction in Own Shares
15th Sep 20237:00 amRNSHalf-year Report
14th Sep 20231:43 pmRNSNet Asset Value(s)
31st Aug 20234:40 pmRNSCompany Secretary Change
29th Aug 20233:46 pmRNSTransaction in Own Shares - Replacement
29th Aug 20232:49 pmRNSTransaction in Own Shares
21st Aug 20233:07 pmRNSTransaction in Own Shares
16th Aug 20234:15 pmRNSTransaction in Own Shares
15th Aug 202310:03 amRNSNet Asset Value(s)
14th Aug 20232:09 pmRNSTransaction in Own Shares
8th Aug 20234:30 pmRNSTransaction in Own Shares
7th Aug 20234:28 pmRNSTransaction in Own Shares
25th Jul 202312:52 pmRNSNanoco Group Plc
18th Jul 20233:23 pmRNSNet Asset Value(s)
17th Jul 202312:41 pmRNSPortfolio Update
10th Jul 20239:39 amRNSTransaction in Own Shares
3rd Jul 202310:14 amRNSTransaction in Own Shares
30th Jun 202312:17 pmRNSDirector/PDMR Shareholding
26th Jun 202310:00 amRNSTransaction in Own Shares
21st Jun 20237:00 amRNSResult of AGM
15th Jun 20231:15 pmRNSNet Asset Value(s)
26th May 20235:10 pmRNSDirectorate Change
22nd May 20231:37 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.